## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.0% below STRENGTH zone (4.0-10.0%); PEG 6.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($372.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Waters Corp Hits 80-Plus Relative Strength Rating Benchmark**
- Source: Investor's Business Daily | 20251211T080839 | Bullish | Relevance: 99%
- Waters Corp (WAT) has achieved an 80-plus Relative Strength (RS) Rating, climbing from 77 to 81. This upgrade indicates improving technical performance and market leadership for the stock. Investors are advised to focus on stocks with an RS Rating of 80 or higher for their watch lists.

**2. Waters Corp. stock rating upgraded to Outperform by Wolfe Research**
- Source: Investing.com UK | 20251210T120902 | Bullish | Relevance: 99%
-  Wolfe Research upgraded Waters Corp. (NYSE:WAT) to Outperform with a $480.00 price target, citing above-average core growth potential, an attractive free cash flow profile, and strong management. Despite potential near-term premium degradation from the BD Life Sciences integration, Wolfe Research believes Waters shares are undervalued due to the company's attractive end market and strong financial prospects. This upgrade follows strong Q3 2025 results that surpassed analyst expectations, leading to adjusted price targets from other investment firms.

**3. Jefferies raises Becton Dickinson stock price target to $220 on deal implications**
- Source: Investing.com India | 20251210T110435 | Somewhat-Bullish | Relevance: 75%
-  Jefferies has increased its price target for Becton Dickinson (NYSE:BDX) to $220 from $215, maintaining a Buy rating, due to implications from its transaction with Waters Corporation. The firm notes that investors are "warming up" to the Waters story, supporting Becton Dickinson's stock, and that the "New BD" remaining business appears to be trading at a "relatively cheap pro forma valuation." This adjustment precedes a webinar to discuss the tax-efficient Reverse Morris Trust structure.

**4. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Finviz | 20251211T130823 | Somewhat-Bullish | Relevance: 67%
- Morgan Stanley analyst Patrick Wood maintained an Overweight rating on Becton, Dickinson and Company (BDX) and raised the price target to $210, citing a positive outlook for the MedTech sector. The company's MedTech division, New BD, is expected to complete its merger with Waters Corporation by Q1 2026, and BDX reported strong Q4 2025 revenues and cash flow, along with significant returns to shareholders.

**5. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Insider Monkey | 20251211T021300 | Neutral | Relevance: 63%
-  Morgan Stanley analyst Patrick Wood increased the price target for Becton, Dickinson and Company (NYSE: BDX) to $210 from $197, maintaining an "Overweight" rating, citing major product cycles, healthier hospital spending, and attractive valuations within the MedTech sector. Becton, Dickinson reported strong Q4 2025 revenues of $5.9 billion, an 8.3% YoY growth, and detailed the merger plans for its Biosciences and Diagnostic Solutions (New BD) with Waters Corporation. The company demonstrated commitment to shareholder value by returning $2.2 billion through dividends and share repurchases.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.42 signals overvaluation risk, limited margin of safety. Forward P/E 27.4x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.4B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.42 |
| Forward P/E | 27.4 |
| Current P/E | 29.9 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.0% to -2.0% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.73), momentum weakening. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.04% (CS: 30) | Weak |
| RSI_14 | 56.8 | Neutral |
| MACD Histogram | -2.73 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.157x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $392.21
- **Stop Loss:** $372.21 (5.1% risk)
- **Target:** $412.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $27,062.49
- **Portfolio %:** 27.06%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*